| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 06/16/2011 | WO2011070970A1 Overexpression inhibitor of thymic stromal lymphopoietin |
| 06/16/2011 | WO2011070565A1 Glucans for treating or preventing food sensitivity |
| 06/16/2011 | WO2011070541A1 Cysteine protease inhibitors |
| 06/16/2011 | WO2011070539A1 Cysteine protease inhibitors |
| 06/16/2011 | WO2011070415A1 Novel therapeutic methods for treating inflammation and immune system disorders |
| 06/16/2011 | WO2011070364A1 Novel cyclic peptides |
| 06/16/2011 | WO2011070339A1 Method of treating disease |
| 06/16/2011 | WO2011070024A1 Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| 06/16/2011 | WO2011069987A1 Infant formula with probiotics and milk fat globule membrane components |
| 06/16/2011 | WO2011047770A3 Pyrazolopyrimidine derivatives |
| 06/16/2011 | WO2011019932A9 Compositions and methods for the therapy and diagnosis of influenza |
| 06/16/2011 | WO2011011733A3 Factor replacement therapy |
| 06/16/2011 | WO2010132561A3 New human rotavirus strains and vaccines |
| 06/16/2011 | US20110144330 2,4-Pyrimidinediamine Compounds and their Uses |
| 06/16/2011 | US20110144309 Manipulation of Cytokine Levels Using CD83 Gene Products |
| 06/16/2011 | US20110144206 Use of a cox-2 inhibitor for the treatment of a cox-2 dependent disorder in a patient not carrying hla alleles associated with hepatotoxicity |
| 06/16/2011 | US20110144183 Oligonucleotides for treating inflammation and neoplastic cell proliferation |
| 06/16/2011 | US20110144170 Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS |
| 06/16/2011 | US20110144157 Pyrrole derivatives, preparation of same and therapeutic application thereof |
| 06/16/2011 | US20110144136 Novel adenine derivatives |
| 06/16/2011 | US20110144116 DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS |
| 06/16/2011 | US20110144115 Substituted 1-benzyl-cinnolin-4(1h)-one derivatives, preparation thereof, and therapeutic use thereof |
| 06/16/2011 | US20110144113 Triazolotriazines as kinase inhibitors |
| 06/16/2011 | US20110144104 Pyrrolidinyl-alkyl-amide derivatives, their preparation, and their therapeutic application as ccr3 receptor ligands |
| 06/16/2011 | US20110144101 Macrocyclic compounds useful as pharmaceuticals |
| 06/16/2011 | US20110144100 Triazolopyridine compounds as pim kinase inhibitors |
| 06/16/2011 | US20110144097 2-amino-5,5-difluoro-5,6-dihydro-4h-[1,3]oxazin-4-yl)-phenyl]-amides |
| 06/16/2011 | US20110144095 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| 06/16/2011 | US20110144083 Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions |
| 06/16/2011 | US20110144074 Caspase inhibitors and uses thereof |
| 06/16/2011 | US20110144059 Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| 06/16/2011 | US20110144039 Antioxidative and hepatoprotective compositions containing diaryheptanoids from alnus japonica |
| 06/16/2011 | US20110144038 Human cd154-binding synthetic peptide and uses thereof |
| 06/16/2011 | US20110144011 Cellular Activation Insulin Therapy |
| 06/16/2011 | US20110143995 Novel anti-allergic agents |
| 06/16/2011 | US20110143431 Method Of Preparing An Undifferentiated Cell |
| 06/16/2011 | US20110142955 Agent for ameliorating stress-induced immune function modulation |
| 06/16/2011 | US20110142953 Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
| 06/16/2011 | US20110142944 Andrographis extract formulations |
| 06/16/2011 | US20110142934 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season |
| 06/16/2011 | US20110142933 Controlled Release Dosage Form of Tacrolimus |
| 06/16/2011 | US20110142914 Inhalable compositions having enhanced bioavailability |
| 06/16/2011 | US20110142911 HIV epitopes and pharmaceutical composition containing same |
| 06/16/2011 | US20110142886 Pegylated polyplexes for polynucleotide delivery |
| 06/16/2011 | US20110142884 Materials and Methods for Making Improved Micelle Compositions |
| 06/16/2011 | US20110142881 Transcutaneous delivery of therapeutic agents |
| 06/16/2011 | US20110142880 Lentivirus-based immunogenic vectors |
| 06/16/2011 | US20110142879 Infectious clones |
| 06/16/2011 | US20110142878 Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use |
| 06/16/2011 | US20110142877 Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents |
| 06/16/2011 | US20110142876 Conjugated vi saccharides |
| 06/16/2011 | US20110142873 Bioactive purified hspe7 compositions |
| 06/16/2011 | US20110142872 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 06/16/2011 | US20110142871 Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| 06/16/2011 | US20110142870 Bacillus anthracis antigens, vaccine compositions, and related methods |
| 06/16/2011 | US20110142869 Membrane proximal region of hiv gp41 anchored to the lipid layer of a virus-like particle vaccine |
| 06/16/2011 | US20110142868 Peptidylarginine Deiminase (PAD) Inhibitors |
| 06/16/2011 | US20110142867 Immunotherapeutic methods and systems |
| 06/16/2011 | US20110142866 Peptide analogues and conjugates thereof |
| 06/16/2011 | US20110142865 Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules |
| 06/16/2011 | US20110142864 Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules |
| 06/16/2011 | US20110142861 Depletion of cd103 expressing cells for treatment of disorders |
| 06/16/2011 | US20110142860 Depletion of CD103 Expressing Cells for Treatment of Disorders |
| 06/16/2011 | US20110142856 Compound containing basic group and use thereof |
| 06/16/2011 | US20110142855 Compounds Having CRTH2 Antagonist Activity |
| 06/16/2011 | US20110142853 Engineered Anti-IL-23p19 Antibodies |
| 06/16/2011 | US20110142852 Multispecific antibodies |
| 06/16/2011 | US20110142850 Method of treating cd40-mediated diseases |
| 06/16/2011 | US20110142847 Methods of Eliciting Broadly Neutralizing Antibodies Targeting HIV-1 GP41 |
| 06/16/2011 | US20110142841 Compositions and methods for the treatment of systemic lupus erythematosis |
| 06/16/2011 | US20110142814 Methods for Using Protein Kinase C-Theta Inhibitors in Adoptive Immunotherapy |
| 06/16/2011 | US20110142806 Electroactive Scaffold |
| 06/16/2011 | US20110142801 Protease resistant modified interferon-beta polypeptides and their use in treating diseases |
| 06/16/2011 | US20110142791 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| 06/16/2011 | US20110142769 Low toxicity topical active agent delivery system |
| 06/16/2011 | US20110142761 Il-1 binding proteins |
| 06/16/2011 | CA2820202A1 Method of reversing immune suppression of langerhans cells |
| 06/16/2011 | CA2783768A1 Infant formula with probiotics and milk fat globule membrane components |
| 06/16/2011 | CA2782898A1 Novel cyclic peptides |
| 06/16/2011 | CA2782294A1 Cysteine protease inhibitors |
| 06/16/2011 | CA2782292A1 Cysteine protease inhibitors |
| 06/16/2011 | CA2782132A1 Methods and compositions using peroxiredoxin 1 (prx1) as an adjuvant |
| 06/16/2011 | CA2781233A1 Novel therapeutic methods for treating inflammation and immune system disorders |
| 06/16/2011 | CA2780692A1 Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| 06/15/2011 | EP2332991A2 Humanized anti-cd4 antibody with immunosuppressive properties |
| 06/15/2011 | EP2332978A1 Novel polypeptides involved in immune response |
| 06/15/2011 | EP2332976A1 Novel polypeptides involved in immune response |
| 06/15/2011 | EP2332962A1 Cyclopenta[g]quinazoline compounds for use in the treatment of inflammatory or allergic conditions |
| 06/15/2011 | EP2332961A2 Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 06/15/2011 | EP2332924A1 Pyrimidine derivates, medicaments comprising them, their use and process of their preparation |
| 06/15/2011 | EP2332922A1 N-substituted azoles and their use as MEK-1 and/or ERK-2 modulators |
| 06/15/2011 | EP2332915A1 Beta2-adrenoceptor agonists |
| 06/15/2011 | EP2332581A1 Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine |
| 06/15/2011 | EP2332579A2 Antibodies that bind human interleukin-18 and methods of making and using |
| 06/15/2011 | EP2332577A1 Novel use of IL-1beta compounds |
| 06/15/2011 | EP2332574A1 HCV NS3/4A Sequences |
| 06/15/2011 | EP2332573A1 Chimeric alphavirus replicon particles |
| 06/15/2011 | EP2332570A1 Compositions and methods for treating neurological disorders |
| 06/15/2011 | EP2332569A2 Compositions and methods for treating neurological disorders |
| 06/15/2011 | EP2332561A1 Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |